Guowen Yin

Guowen Yin


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2024 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
LDLingfeng Diao
Lingfeng Diao
CWChendong Wang
Chendong Wang
RYRan You
Ran You
BLBin Leng
Bin Leng
ZYZeyu Yu
Zeyu Yu
GYGuowen Yin
Guowen Yin

5 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RYRan You
Ran You
YYYanjun Yang
Yanjun Yang
GYGuowen Yin
Guowen Yin
HJHao Jiang
Hao Jiang
YLYousheng Lu
Yousheng Lu
LFLiang Feng
Liang Feng
Hepatocellular carcinoma (HCC) is a prevalent and high-mortality cancer worldwide, and its complexity necessitates novel strategies for drug selection and design. Current approaches primarily focus on reducing gene expression, while promoting gene overexpression remains a challenge. In this work, we studied the effect of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in HCC by constructing tissue microarrays (TAMs) from 90 HCC cases and corresponding para-cancerous tissues. Our analysis showed that CPEB2 expression was significantly reduced in HCC tissues, and its low expression was associated with a higher recurrence risk and poorer prognosis in patients with head and neck cancer. CPEB2 was found to regulate HCC epithelial–mesenchymal transition (EMT) and metastasis through the HIF-1α/miR-210-3p/CPEB2 feedback circuit. Using the RNA binding protein immunoprecipitation (RIP) assay, we demonstrated that miR-210 directly governs the expression of CPEB2. The inverse relationship between CPEB2 expression and miR-210-3p in HCC tissues suggested that this regulatory mechanism is directly linked to HCC metastasis, EMT, and clinical outcomes. Moreover, utilizing the SM2miR database, we identified drugs that can decrease miR-210-3p expression, consequently increasing CPEB2 expression and providing new insights for drug development. In conclusion, our findings illustrated a novel HIF-1α/miR-210-3p/CPEB2 regulatory signaling pathway in HCC and highlighted the potential of enhancing CPEB2 expression through targeting miR-210-3p as a novel predictive biomarker and therapeutic strategy in HCC, as it is modulated by the HIF-1α/miR-210-3p/CPEB2 feedback circuit.

19 September 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
RYRan You
Ran You
YCYuan Cheng
Yuan Cheng
LDLingfeng Diao
Lingfeng Diao
CWChendong Wang
Chendong Wang
BLBin Leng
Bin Leng
GYGuowen Yin
Guowen Yin
Purpose: In the present study, we aimed to assess the effectiveness and safety of immune-targeted therapy (IT) with or without transarterial chemoembolization (TACE) for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). Patients and methods: This was a multicenter retrospective study that included 265 HCC patients with PVTT (IT + TACE: 82, IT: 183). Overall survival (OS) and progression-free survival (PFS), as well as tumor responses and adverse events, were evaluated. Results: Patients in the IT + TACE group experienced significantly longer overall survival (OS) and progression-free survival (PFS) periods, compared with those in the IT group (OS 19.0 vs. 13.0 months, p < 0.001; PFS 12.0 vs. 7.3 months, p < 0.001). Multivariable analysis confirmed IT + TACE as an independent predictor for improved OS and PFS. Subgroup analysis demonstrated the benefits of IT + TACE in patients with rich PVTT blood supply. Preoperative imaging and DSA offered predictive value. Conclusions: TACE combined with IT provides a safe and effective treatment option for advanced-HCC patients with PVTT, particularly those with abundant PVTT blood supply.

16 May 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
QXQingyu Xu
Qingyu Xu
CWChendong Wang
Chendong Wang
RYRan You
Ran You
BLBin Leng
Bin Leng
ZYZeyu Yu
Zeyu Yu
GYGuowen Yin
Guowen Yin
Background Unresectable intrahepatic cholangiocarcinoma (iCCA) is characterized with dismal prognosis. Here, this study aimed to compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and PD-1 inhibitors versus systemic chemotherapy (SC) for unresectable iCCA. Methods Patients with histologically confirmed unresectable iCCA from January 2020 to December 2022 at our center were retrospectively enrolled. Propensity score matching (PSM) method was used to balance clinicopathological information between two groups. The primary endpoints were overall survival (OS), progression-free survival (PFS), whereas the secondary endpoints included objective response rate (ORR), disease-control rate (DCR) and safety profiles. Factors affecting the survival were identified through univariate and multivariate analyses. Results Eighty-six cases were included in this study. After PSM, there were 30 patients in each group. Compared to SC group, HAIC + Len + PD-1 inhibitor exhibited significantly improved OS (16.91 [95%CI: 11.6–28.4] months vs. 11.06 months [95%CI: 7.8–14.6 months], p = 0.011), PFS (11.17 months [95%CI: 7.0, 26.7] vs. 5.55 months [95%CI: 3.8, NA], p = 0.004), better ORR (56.7% vs. 23.3%, p = 0.008) and DCR (93.3% vs. 70.0%, p = 0.019). Multivariate analysis indicated that treatment arm of SC was a risk factor of worse OS and PFS, while uni-lobe tumor distribution, AST ≤ 40, CA19-9 level ≤ 39 were protective factors of worse OS. All adverse events were comparable and controllable between two groups. Conclusions In conclusion, HAIC combined with lenvatinib and PD-1 blockade yields better tumor control and survival outcomes over SC for unresectable iCCA, with manageable adverse events as well.

8 August 2025 in Discover Oncology
Verified
Journal Article
Open access
QXQingyu Xu
Qingyu Xu
BLBin Leng
Bin Leng
RYRan You
Ran You
LDLingfeng Diao
Lingfeng Diao
CWChendong Wang
Chendong Wang
GYGuowen Yin
Guowen Yin
To demonstrate the potential benefits of additional transarterial chemoembolization (TACE) for advanced hepatocellular carcinoma (HCC) after the failure of first-line systemic treatment (ST). This retrospective single-center study was conducted between January 2020 and December 2022 on patients with advanced HCC who failed to respond to initial first-line ST. Patients who had previously undergone TACE were excluded. Eligible patients underwent on-demand TACE in addition to ST and were followed until death or until March 2023. The duration of response was recorded. Overall survival (OS) was calculated from the date of failure of first-line ST to the date of death or last follow-up. The primary outcomes were OS and safety, and the secondary outcomes were time to progression (TTP) and objective response rate (ORR). In total, 18 patients were included; 8 patients had failed to respond to lenvatinib or sorafenib monotherapy, and 10 had failed to respond to a combination therapy. The most common progression pattern was the development of new intrahepatic lesions. Salvage treatment consisted of 16 triple therapies and 2 dual therapies, including TACE. The median duration of follow-up was 9.5 months. The median OS from the start of second-line treatment was 24 months. The median TTP was 3.5 months. The ORR was 55.6%, and disease control was achieved in 94.4% of patients. Treatment-related adverse events were common but acceptable. Patients with advanced HCC who face significant treatment challenges could potentially benefit from the addition of TACE to second-line ST.

10 April 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
RYRan You
Ran You
BLBin Leng
Bin Leng
CWChendong Wang
Chendong Wang
ZYZeyu Yu
Zeyu Yu
LDLingfeng Diao
Lingfeng Diao
GYGuowen Yin
Guowen Yin
Objective This study aimed to compare the extent of liver injury and the inflammatory response in patients with hepatocellular carcinoma (HCC) following conventional transarterial chemoembolization (cTACE) and drug-eluting bead transarterial chemoembolization (DEB-TACE). Methods Clinical data from October 2018 to October 2019 were prospectively collected to establish a database. The baseline clinical and demographic characteristics of patients in the two groups were matched using propensity score matching (PSM). Serum levels of hepatic function indicators and inflammatory cytokines were evaluated before treatment and five days post-treatment. Results A total of 134 participants were included in the analysis. Following 1:1 PSM, 43 patients remained in each group, with no significant differences observed in baseline characteristics. The median absolute concentration of aspartate aminotransferase (AST) was significantly lower in the DEB-TACE group five days after treatment. Among 18 patients who experienced idiosyncratic drug-induced liver injury, the DEB-TACE group exhibited a significantly lower proportion of cases. The alanine aminotransferase/alkaline phosphatase (ALT/ALP) ratio was notably higher in the cTACE group, while cholestatic-type liver injuries were predominant in the DEB-TACE group. Levels of MCP-1, IL-6, and IL-1β were lower in the DEB-TACE group five days post-treatment. Additionally, MCP-1 levels were significantly correlated with ALT levels and the type of liver injury. Similarly, IL-6 levels showed significant correlations with ALT, AST, and the type of liver injury. Conclusions DEB-TACE was associated with reduced acute liver injury, characterized primarily by cholestatic injury, and a milder inflammatory response compared to cTACE. Post-treatment levels of MCP-1 and IL-6 levels were correlated with aminotransferase levels and the type of liver injury. Trial registration: Chinese Clinical Trial Registry, ChiCTR-1800017781. Register URL link: https://www.chictr.org.cn/showproj.html?proj=30041. Register date: 2018-8-14.